Welcome to the pharmaceutical industry area of the MHRA website. This section, which has been developed following feedback from users, provides targeted links to information throughout the site, as well as content relevant to the industry.
If you have any feedback on this section and how we can improve it please email webusability@mhra.gsi.gov.uk or fill out our feedback form.
There is a link at the top of every page of the MHRA website which links directly to this section.
News and hot topics
16 May 2013 | Changes to medicines names: sulphate to sulfate
Further to the nomenclature harmonisation in 2003/04 Changes to medicines names: BANs to rINNs, the European Pharmacopoeia and British Pharmacopoeia have amended the spelling of sulphate to sulfate for all products containing sulfate (or sulfur containing compounds eg sulfonate).
25 Apr 2013 | EU additional monitoring list for medicines
The Pharmacovigilance Risk Assessment Committee (PRAC) has published the European so-called ‘mandatory’ list of medicines under additional monitoring.
14 Mar 2013 | Guidance on submitting label and leaflet mock-ups following variations
In April 2012, following consultation with medicines trade associations and member companies we announced some procedural changes concerning the requirement to submit full-colour mock-ups of labels and patient leaflets. In the last year we have received a number of requests for a copy of the guidance, which we have now published on our website.
14 Mar 2013 | Joint BIA/MHRA Conference: Innovation in the development and regulation of biopharmaceuticals
The third joint BIA and MHRA conference will focus on supporting innovation in the development and regulation of biopharmaceuticals from both regulatory and life sciences industry perspectives.
11 Mar 2013 | Press release: MHRA launches an ‘Innovation Office’ to encourage the development of novel medical products and devices
The MHRA is launching an ‘Innovation Office’ to help organisations who are developing innovative medicines, medical devices or using novel manufacturing processes to navigate the regulatory processes in order to be able to progress their products or technologies.
Fees
Clinical trials
Post marketing authorisation approval
Herbal, homeopathic and borderline medicines
Manufacturing and wholesaling
Contacting the MHRA
Legislation, guidance and policy
Applying for a marketing authorisation
Product information and advertising
Inspection
Safety and pharmacovigilance
Over-the-counter medicines
Medicines for children



